Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML

Dec. 11

Written By Maria Parshenkova

Download Poster

Maria Parshenkova

A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax

EILEAN THERAPEUTICS DOSES FIRST PATIENT WITH ZE46-0134, A SELECTIVE FLT3wt-SPARING, PAN FLT3mut INHIBITOR